• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Risk-to-Price Commentary: Cegedim S.A. Mar 11 Product Image

Risk-to-Price Commentary: Cegedim S.A. Mar 11

  • Published: March 2011
  • Standard & Poors

FEATURED COMPANIES

  • AstraZeneca PLC
  • Bayer AG
  • Bayer Capital Corp. B.V.
  • Bristol-Myers Squibb Co.
  • Cegedim S.A.
  • FMC Finance VII S.A.
  • MORE

Abstract
On March 15, the Center for European Economic Research in Mannheim (CEER) released the ZEW index of investor and analyst expectations for Germany. The index declined to 14.1 from 15.7 in February. Economists expected that the index would increase to 15.9 (see chart 1). The ZEW index aims to predict developments six months in advance. We consider this index to be a meaningful indicator of the investment sentiment for all of Europe, because Germany accounts for about a quarter of the GDP in Europe and is growing faster than most of the European Union. Moreover, CEER pointed out that after the earthquake and tsunami in Japan on March 11, the survey responses that came in were significantly more pessimistic than...

Companies mentioned in this report are:
- Bristol-Myers Squibb Co.
- Pfizer Inc.
- Millipore Corp.
- Bayer AG
- GlaxoSmithKline Capital PLC
- AstraZeneca PLC
- Sanofi
- Bayer Capital Corp. B.V.
- Novartis Finance S.A.
- Roche Finance Europe B.V.
- Merck Financial Services GmbH
- Cegedim S.A.
- FMC Finance VII S.A.

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, READ MORE >

- Bristol-Myers Squibb Co.
- Pfizer Inc.
- Millipore Corp.
- Bayer AG
- GlaxoSmithKline Capital PLC
- AstraZeneca PLC
- Sanofi
- Bayer Capital Corp. B.V.
- Novartis Finance S.A.
- Roche Finance Europe B.V.
- Merck Financial Services GmbH
- Cegedim S.A.
- FMC Finance VII S.A.

Note: Product cover images may vary from those shown

RELATED PRODUCTS